Conduit C, Bagrodia A, Hamilton RJ, Feldman DR, Tran B. Optimal Management of Stage II Seminoma: Preventing Harm While Preserving Cure.JCO Oncology Practice. 2025;:10.1200/op-25-00252
Williams C, Inderjeeth A-J, Hong W, McKenzie J, Anton A, Weickhardt A, Wong S, Shapiro J, Parente P, Goh J, Torres J, Smith A, Joshua A, Brown S, Steer C, Johns J, Gibbs P, Tran B, Azad AA. Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 2025;23(3):10.1016/j.clgc.2025.102345
Weickhardt AJ, Foroudi F, Lawrentschuk N, Xie J, Ko Y-A, Sidhom M, Pal A, Grimison PS, Zhang AY, Ng S, Tang C, Hovey EJ, Chen C, Hruby G, Guminski AD, Oakes SR, Conduit C, Tran B, Davis ID, Hayne D. Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.4577
Buteau JP, Kostos LK, Jackson P, McIntosh L, Alipour R, Akhurst TJ, Eifer M, Emmerson B, Haskali MB, Jewell K, Kashyap R, Kong G, Murphy D, Ravi Kumar AS, Saghebi J, Sandhu S, Tran B, Xie J, Azad A, Hofman MS. First-in-human results of terbium-161[ 161 Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.5010
Tran B, Frentzas S, Lemech CR, Millward M, Day D, Desai J, Latifi A, Wabnitz P, Kearney P, Galkin AV. Abstract 5850: AXA-042, a systemically administered TLR2/6 agonist, demonstrates innate immune engagement and Th1 polarization in patients with advanced solid tumors. Cancer Research. 2025;85(8_Supplement_1):10.1158/1538-7445.am2025-5850
Conduit C, Hutchinson AD, Leonard M, O.’Haire S, Moody M, Thomas B, Sim I, Hong W, Ahmad G, Lawrentschuk N, Lewin J, Tran B, Dhillon HM. An exploration of testicular cancer survivors’ experience of ejaculatory dysfunction following retroperitoneal lymph node dissection—a sub-study of the PREPARE clinical trial. Journal of Cancer Survivorship. 2025;19(2):10.1007/s11764-023-01489-9
Eifer M, Sutherland DEK, Goncalves I, Buteau JP, Au L, Azad AA, Emmett L, Kong G, Kostos L, Ravi Kumar AS, Kwan EM, Medhurst E, Sandhu S, Tran B, Wyatt AW, Hofman MS. Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.Journal of Nuclear Medicine. 2025;66(4):10.2967/jnumed.124.268640
Udovicich C, Bressel M, Manji J, Ali M, Au L, Azad AA, Buteau JP, Chander S, Chang D, Eapen R, Lawrentschuk N, Levy SM, Moon D, Murphy DG, Perera M, Shaw M, Spain L, Tran B, Hofman MS, Siva S. PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study.Journal of Nuclear Medicine. 2025;66(4):10.2967/jnumed.124.268639
Kostos L, Buteau JP, Kong G, Tran B, Haskali MB, Fahey M, Crumbaker M, Emmett L, Hofman MS, Azad AA. Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.Journal of Nuclear Medicine. 2025;66(4):10.2967/jnumed.124.269252
Abdul Aziz N, Ng K, Alifrangis C, Tran B, Conduit C, Liow ECH, Ackerman C, Georgescu R, Jamal T, Relton C, Mayer E, Nicol D, Cazzaniga W, Huddart RA, Reid AH, Shamash J, Rajan P. THERATEST: A multi-centre observational cohort feasibility study of de-escalation therapies for stage II seminoma.Journal of Clinical Oncology. 2025;43(5_suppl):10.1200/jco.2025.43.5_suppl.tps651
